Blue Trust Inc. Buys 21,958 Shares of Elanco Animal Health Incorporated $ELAN

Blue Trust Inc. grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1,436.1% during the first quarter, Holdings Channel reports. The institutional investor owned 23,487 shares of the company’s stock after buying an additional 21,958 shares during the period. Blue Trust Inc.’s holdings in Elanco Animal Health were worth $562,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC raised its stake in Elanco Animal Health by 4.2% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock worth $342,000 after acquiring an additional 579 shares during the period. OP Asset Management Ltd purchased a new position in Elanco Animal Health during the first quarter valued at approximately $8,171,000. Corient Private Wealth LLC boosted its position in shares of Elanco Animal Health by 35.6% in the fourth quarter. Corient Private Wealth LLC now owns 100,895 shares of the company’s stock worth $2,283,000 after purchasing an additional 26,507 shares during the period. Kera Capital Partners Inc. boosted its position in shares of Elanco Animal Health by 79.0% in the fourth quarter. Kera Capital Partners Inc. now owns 21,735 shares of the company’s stock worth $523,000 after purchasing an additional 9,595 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its stake in shares of Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent analyst reports. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. TD Cowen lifted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, Citigroup boosted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by insiders.

Elanco Animal Health Stock Up 0.8%

Shares of NYSE ELAN opened at $24.56 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72. The firm’s 50-day moving average price is $23.04 and its 200-day moving average price is $23.56. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of -49.12, a P/E/G ratio of 1.61 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.